Jump Financial LLC Takes Position in Caribou Biosciences, Inc. (NASDAQ:CRBU)

Jump Financial LLC acquired a new stake in shares of Caribou Biosciences, Inc. (NASDAQ:CRBUFree Report) during the third quarter, HoldingsChannel reports. The fund acquired 92,204 shares of the company’s stock, valued at approximately $441,000.

A number of other large investors also recently modified their holdings of CRBU. Swiss National Bank raised its holdings in shares of Caribou Biosciences by 8.0% during the 1st quarter. Swiss National Bank now owns 57,000 shares of the company’s stock valued at $523,000 after buying an additional 4,200 shares in the last quarter. ProShare Advisors LLC raised its holdings in shares of Caribou Biosciences by 22.1% during the 1st quarter. ProShare Advisors LLC now owns 15,766 shares of the company’s stock valued at $145,000 after buying an additional 2,856 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Caribou Biosciences by 2,754.9% during the 1st quarter. JPMorgan Chase & Co. now owns 515,758 shares of the company’s stock valued at $4,735,000 after buying an additional 497,692 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Caribou Biosciences by 108.2% during the 1st quarter. Bank of New York Mellon Corp now owns 141,262 shares of the company’s stock valued at $1,297,000 after buying an additional 73,427 shares in the last quarter. Finally, MetLife Investment Management LLC raised its holdings in shares of Caribou Biosciences by 311.7% during the 1st quarter. MetLife Investment Management LLC now owns 31,003 shares of the company’s stock valued at $285,000 after buying an additional 23,472 shares in the last quarter. 59.16% of the stock is owned by hedge funds and other institutional investors.

Caribou Biosciences Price Performance

Shares of Caribou Biosciences stock opened at $6.93 on Friday. The business’s 50 day simple moving average is $5.84 and its two-hundred day simple moving average is $5.52. The stock has a market capitalization of $612.83 million, a P/E ratio of -4.62 and a beta of 2.50. Caribou Biosciences, Inc. has a one year low of $3.44 and a one year high of $8.59.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Cantor Fitzgerald assumed coverage on Caribou Biosciences in a report on Wednesday, November 8th. They set a “neutral” rating on the stock. Evercore ISI initiated coverage on Caribou Biosciences in a research note on Tuesday, October 31st. They issued an “outperform” rating and a $13.00 price target on the stock. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $23.57.

Check Out Our Latest Analysis on Caribou Biosciences

Caribou Biosciences Company Profile

(Free Report)

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma.

Recommended Stories

Want to see what other hedge funds are holding CRBU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Caribou Biosciences, Inc. (NASDAQ:CRBUFree Report).

Institutional Ownership by Quarter for Caribou Biosciences (NASDAQ:CRBU)

Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.